论文部分内容阅读
目的 探索能通过血脑屏障的高效低毒抗肿瘤药物。方法 美蓝组:美蓝400mg静滴,第1、3、5、13、15、17天;DDP100mg～120mg/m~2静滴,第7天;ADM40mg～60mg静滴,第7天;VP—16100mg静滴,第7～11天,即HD—MeDAE方案治疗肺癌脑转移34例。对照组:将上述方案中除美蓝不用外其它药物药量用法不变,即DAE方案治疗肺癌脑转移24例。结果 美蓝组经1～6个疗程,平均2.8个疗程化疗肺原发癌灶达CR1例,PR21例,有效缓解率64.7％,脑转移灶CR 2例,PR23例,有效缓解率73.5％;对照组经1～5个疗程,平均3.2个疗程化疗肺原发癌灶达CR2例,PR14例,有效缓解率66.6％,脑转移灶PR5例,有效缓解率20.8％。经统计学处理脑转移癌灶缓解率美蓝组高于对照组,其差异有高度显著性(P<0.01)。结论 美蓝对脑转移癌治疗有效。
Objective To explore highly effective low-toxicity anti-tumor drugs that can pass through the blood-brain barrier. Methods Methylene blue group: Methylene blue 400mg intravenous infusion, days 1, 3, 5, 13, 15, and 17; DDP 100mg to 120mg/m~2 intravenous infusion, day 7; ADM 40mg to 60mg intravenous infusion, day 7; VP - Intravenous infusion of 16100 mg, on the 7th to 11th days, the HD-MeDAE regimen was used to treat 34 cases of brain metastases from lung cancer. Control group: In the above protocol, except for methylene blue, the dose of other drugs was not changed. That is, DAE regimen was used to treat 24 cases of brain metastases from lung cancer. Results After 1 to 6 courses of treatment in the methylene blue group, the average number of chemotherapeutic lung lesions in the 2.8 cycles was 1 CR and 21 PR, the effective response rate was 64.7%, 2 cases of brain metastases were CR, and 23 cases were PR. The effective response rate was 73.5%. In the control group, after 1 to 5 courses of treatment, the average 3.2 treatment cycles of primary lung cancer were CR2 cases, PR14 cases, effective remission rate 66.6%, 5 cases of brain metastases PR, effective response rate was 20.8%. The statistical treatment of the brain metastases tumor remission rate methylene blue group was higher than the control group, the difference was highly significant (P <0.01). Conclusion Methylene blue is effective in the treatment of brain metastases.